LOS ANGELES, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)THE PITUITARY SOCIETY INC, founded in 1994, is a small nonprofit in the Diseases & Disorders sector that reported $754K in total revenue in fiscal year 2024. Revenue surged 37% from the prior year, signaling strong growth momentum. The organization ran a surplus of $270K, a strong 36% operating margin.
OUR MISSION IS TO PROVIDE SCIENTISTS, CLINICIANS AND TRAINEES WITH THE MOST UP-TO-DATE, RELIABLE RESEARCH AND EDUCATION ON THE BIOLOGY OF THE PITUITARY GLAND AND THE CAUSES, DIAGNOSIS AND TREATMENT OF PITUITARY GLAND RELATED DISEASES, IN ORDER TO IMPROVE PATIENT CARE AND TO PROVIDE A UNIQUELY INTERNATIONAL FORUM FOR PROFESSIONAL GROWTH AND SCIENTIFIC EXCHANGE.
GROPRO CONFERENCETHE GROWTH HORMONE (GH)/ PROLACTIN (PRL) FAMILY IN BIOLOGY & DISEASE CONFERENCE (GROPRO) WAS HELD AUGUST 11-15, 2024, IN STIRLING, SCOTLAND. THIS CONFERENCE USED TO BE ASSOCIATED...
GROPRO CONFERENCETHE GROWTH HORMONE (GH)/ PROLACTIN (PRL) FAMILY IN BIOLOGY & DISEASE CONFERENCE (GROPRO) WAS HELD AUGUST 11-15, 2024, IN STIRLING, SCOTLAND. THIS CONFERENCE USED TO BE ASSOCIATED WITH FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY (FASEB) AND BEFORE THAT WITH THE GORDON CONFERENCES. SO, IT HAS LONG HISTORY, OVER 2 DECADES. THIS ITERATION OF THE CONFERENCE WAS HELD IN ASSOCIATION WITH THE PITUITARY SOCIETY. THIS CONFERENCE WAS HELD IN EUROPE FOR THE FIRST TIME WITH OVER 90 SCIENTISTS, PHYSICIANS, AND TRAINEES IN ATTENDANCE.THE SCIENTIFIC THEME OF THIS CONFERENCE IS TO IMPROVE OUR UNDERSTANDING OF THE REGULATION AND ACTION OF GH AND PRL AND THEIR SPECIFIC RECEPTORS AS WELL AS THEIR ROLE IN DISEASE PROMOTION OR PREVENTION.
PRECEPTORSHIP COURSE FOR FELLOWS-IN-TRAININGTHIS COURSE, HELD IN JANUARY 2025, WAS THE SEVENTH SINCE ITS INCEPTION. THE COURSE WAS ATTENDED BY APPROXIMATELY 225 FELLOWS-IN-TRAINING. FELLOWS WERE...
PRECEPTORSHIP COURSE FOR FELLOWS-IN-TRAININGTHIS COURSE, HELD IN JANUARY 2025, WAS THE SEVENTH SINCE ITS INCEPTION. THE COURSE WAS ATTENDED BY APPROXIMATELY 225 FELLOWS-IN-TRAINING. FELLOWS WERE REQUIRED TO SUBMIT AN INTERESTING PITUITARY CASE TO ATTEND THE COURSE. CASES WERE REVIEWED BY FACULTY AND FOUR-TO-SIX WERE SELECTED TO BE PRESENTED BY THE FELLOWS DURING THE CASE DISCUSSION. FACULTY RECORDED PRESENTATIONS ON ALL PITUITARY PATHOLOGY WERE VIEWED BY THE FELLOWS PRIOR TO THE LIVE WEBINARS TO ALLOW FOR MORE INTERACTIVE LEARNING.OVER THE LAST DECADE, MANY ENDOCRINOLOGY FELLOWSHIP PROGRAMS REDUCED THE TRAINING REQUIREMENTS FROM 3 YEARS TO 2 YEARS TO BE ELIGIBLE FOR BOARD CERTIFICATION. IN PARALLEL, DIABETES AND OBESITY INCIDENCE AND PREVALENCE INCREASED SIGNIFICANTLY, LIMITING CLINICAL EXPERIENCES ON OTHER RARER, NEVERTHELESS SEVERE AND POTENTIALLY LETHAL DISEASES, SUCH AS PITUITARY DISORDERS. THEREFORE, THIS COURSE TAUGHT BY LEADING INTERNATIONAL EXPERTS, ADDRESSED SOME OF THESE ISSUES BY REVIEWING FOR TRAINEES ADVANCEMENTS IN DIAGNOSIS AND TREATMENT OF HYPOPITUITARISM, GROWTH HORMONE DEFICIENCY, CUSHING'S SYNDROME AND ACROMEGALY AS WELL AS MANAGEMENT OF PITUITARY DISEASE IN THE POST-COVID ERA.
PITUITARY SOCIETY CONSENSUS GUIDELINE FOR PITUITARY INCIDENTALOMAS (PUBLISHED GUIDELINE)WITHIN THE CONSTRAINTS OF LIMITED EVIDENCE-BASED REPORTS, THIS PITUITARY SOCIETY CONSENSUS SUMMARIZES THE...
PITUITARY SOCIETY CONSENSUS GUIDELINE FOR PITUITARY INCIDENTALOMAS (PUBLISHED GUIDELINE)WITHIN THE CONSTRAINTS OF LIMITED EVIDENCE-BASED REPORTS, THIS PITUITARY SOCIETY CONSENSUS SUMMARIZES THE EPIDEMIOLOGY AND NATURAL HISTORY, DIAGNOSTIC WORK-UP, AND TREATMENT OPTIONS FOR PATIENTS WITH PITUITARY INCIDENTALOMAS. WE DISTINGUISH BETWEEN PITUITARY ADENOMAS AND OTHER TYPES OF INCIDENTALOMAS AND PARTICULARLY DISTINGUISH BETWEEN MICROADENOMAS AND MACROADENOMAS GIVEN THE LOWER LIKELIHOOD OF THE LATTER TO BE A TRULY INCIDENTAL FINDING.THE GUIDELINES WERE PUBLISHED IN NATURE REVIEWS ENDOCRINOLOGY.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $753,709 | $551,129 | +0.4% |
| Expenses | $483,415 | $488,822 | 0.0% |
| Net Income | $270,294 | $62,307 | +3.3% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| RICHARD ROSS MBBS MD FRCP | PRESIDENT | 6.00 |
Officer
Director
|
$0 | $0 | $0 |
| SHLOMO MELMED MB CHB MACP FRCP | SECRETARY-TREASURER | 6.00 |
Officer
Director
|
$0 | $0 | $0 |
| KEN HO MD | CO-DIRECTOR, PROGRAMS | 0.30 |
Officer
Director
|
$0 | $0 | $0 |
| MARIA FLESERIU MD FACE | CO-DIRECTOR, PROGRAMS | 0.30 |
Officer
Director
|
$0 | $0 | $0 |
| FELIPE F CASANUEVA MD PHD | INTERNATIONAL RELATIONS | 0.30 |
Officer
Director
|
$0 | $0 | $0 |
| ANDREA GIUSTINA MD | EDITOR, PITUITARY | 0.30 |
Officer
Director
|
$0 | $0 | $0 |
| NIENKE BIERMASZ MD PHD | DIRECTOR | 0.30 |
Director
|
$0 | $0 | $0 |
| ELIZA GEERMD | DIRECTOR | 0.30 |
Director
|
$0 | $0 | $0 |
| LISA NACHTIGALL MD | DIRECTOR | 0.30 |
Director
|
$0 | $0 | $0 |
| ROSARIO PIVONELLO MD PHD | DIRECTOR | 0.30 |
Director
|
$0 | $0 | $0 |
| GUDMUNDUR JOHANNSSON MD PHD | DIRECTOR | 0.30 |
Director
|
$0 | $0 | $0 |
| ANN MCCORMACK MBBS | DIRECTOR | 0.30 |
Director
|
$0 | $0 | $0 |
| KEVIN YUEN MD | DIRECTOR | 0.30 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $753,709 | $483,415 | $3,079,505 | $270,294 |
| 2024 | $551,129 | $488,822 | $2,128,717 | $62,307 |
| 2023 | $798,095 | $549,749 | $2,298,432 | $248,346 |
| 2022 | $287,129 | $206,827 | $1,840,975 | $80,302 |
| 2021 | $725,632 | $269,494 | $1,765,158 | $456,138 |
| 2020 | $447,437 | $236,740 | $1,458,060 | $210,697 |
| 2019 | $959,994 | $659,846 | $1,185,286 | $300,148 |
| 2018 | $108,569 | $255,740 | $931,391 | $-147,171 |
Compare THE PITUITARY SOCIETY INC with other nonprofits in California and across the country.